Related Scientific Publications

18.05.2023 / VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe (Vaccine):

03.04.2023 / Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCELERATE Toolkit (JMIR Publications):

07.12.2022 / Efficacy and safety of COVID‐19 vaccines (Cochrane Library):

11.2022 / Performance and validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection or vaccination (Journal of Immunological Methods):

10.2022 / Monkeypox diagnostic and treatment capacity at epidemic onset: A VACCELERATE online survey (Journal of Infection and Public Health):

08.10.2022 / A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network (Trials):

19.09.2022 / Monkeypox in children and adult women in Europe: Results from a flash VACCELERATE pilot survey (Enfermedades Infecciosas y Microbiología Clínica):

31.08.2022 / Vaccination rates in Europe are not associated with online media intensity (JCOM Journal of Science Communication):

18.06.2022 / A pilot surveillance report of SARS-CoV-2 rapid antigen test results among volunteers in Germany, 1st week of July 2022 (Infection):

02.06.2022 / VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment (Vaccine):

11.01.2022 / Factors that impact on recruitment to vaccine trials during a pandemic or epidemic: a qualitative evidence synthesis (Cochrane Library):

29.07.2021 / Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 (The Lancet Infectious Diseases):

27.05.2021 / Reactogenicity and Immunogenicity of BNT162b2 in Subjects Having Received a First Dose of ChAdOx1s: Initial Results of a Randomised, Adaptive, Phase 2 Trial (CombiVacS) (The Lancet):